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This article has been removed: please see Elsevier Policy on Article Withdrawal 
(http://www.elsevier.com/locate/withdrawalpolicy). 
 
This abstract has been removed at the request of the Editor-in-Chief and author 
because it contains a drug dosage error which could have serious health 
consequences.  The abstract contained a dosage error for the drug, docetaxel.   
 
The corrected abstract should read as follows: 
 
Background: We evaluated the efficacy of nimotuzumab combined with docetaxel 
and carboplatin (TP) for treatment of advanced non-small-cell-lung-cancer (NSCLC), 
as well as the effect on circulating blood markers and patient’s side-effects. 
Methods: 21 patients with advanced NSCLC were enrolled in the study. Patients were 
given nimotuzumab (200 mg/week for 6 weeks) and DP regimen (60 mg/m2 docetaxel 
and 400 mg/m2 carboplatin, twice). Each patient had two cycles of chemotherapy. 
Response data was collected before and after treatment. Tumour size and reduction 
were recorded by thoracic CT scan and compared. Treatment related side-effects were 
compared by statistical methods. 
Findings: Tumour size and levels of CEA, NSE, and CYFR21-1 were decreased after 
treatment (p=0.01, p=0.02, p=0.03). Four patients had a complete response, five had a 
partial response, nine had stable disease, and three had progressive disease. Three 
patients had side-effects on facial skin and were graded as stage I–II disease. 
Interpretation: Nimotuzumab combined with DP regimen may increase the efficacy 
of treatment, with few side-effects. 
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